C Number:

Study Gender:

PWG Approval Date

PA49: Summary of Cytochrome Activity Test Compound: 2,2',4,4'-Tetrabromodiphenyl Ether CAS Number: 5436-43-1

C98090C-01 Male See web page for date of PWG Approval Date Report Requested: 03/11/2019 Time Report Requested: 15:21:47 Lab: Battelle

PA49: Summary of Cytochrome Activity Test Compound: 2,2',4,4'-Tetrabromodiphenyl Ether CAS Number: 5436-43-1 Date Report Requested: 03/11/2019 Time Report Requested: 15:21:47 Lab: Battelle

	Male: Core Males									
	Treatment Groups (mg/kg)									
	0		0.048	5	0.48	5	4.85		48	.5
Total Protein Concentration (mg/ml)	7.27 ±	1.03 (6)	8.37 ±	0.91 (6)	6.98 ±	0.80 (6)	8.69 ±	1.06 (6)	9.97 ±	1.18 (6)
Cytochrome P450 1A1 Concentraion (ng/ml)	18.6 ±	1.4 (6)	18.9 ±	0.8 (5)	19.3 ±	0.5 (6)	20.8 ±	1.2 (6)	22.1 ±	1.9 (6)
Cytochrome P450 1A1 Tissue Concentration (ng/mg)	2.790 ±	0.379 (6)	2.773 ±	0.434 (6)	2.935 ±	0.315 (6)	2.552 ±	0.271 (6)	2.327 ±	0.306 (6)
Cytochrome P450 2B1 Concentration (ng/ml)	3.20 ±	0.05 (6)	3.41 ±	0.19 (6)	3.39 ±	0.23 (6)	3.45 ±	0.21 (6)	3.14 ±	0.07 (6)
Cytochrome P450 2B1 Tissue Concentration (ng/mg)	0.496 ±	0.081 (6)	0.424 ±	0.042 (6)	0.511 ±	0.049 (6)	0.424 ±	0.048 (6)	0.335 ±	0.037 (6)
Cytochrome P450 1A2 Concentration (ng/ml)	48.7 ± 1	14.5 (6)	49.0 ±	8.7 (6)	39.2 ±	4.9 (6)	36.9 ±	4.1 (6)	55.3 ±	15.8 (6)
Cytochrome P450 1A2 Tissue Concentration (ng/mg)	6.762 ±	1.700 (6)	5.973 ±	1.043 (6)	5.988 ±	0.879 (6)	4.757 ±	0.975 (6)	5.808 ±	1.756 (6)
UDP Glucuronosyltransferase 1 Concentration (ng/ml)	15048.917 ± 145	53.437 (6) **	16626.417 ± 23	304.970 (6)	14805.417 ± 1	592.598 (6)	16437.750 ± 17	793.113 (6)	25644.667 ± 2	938.265 (6) **
UDP Glucuronosyltransferase 1 Tissue Concentration (ng/mg)	2376.768 ± 48	87.613 (6)	2092.099 ± 3	370.681 (6)	2282.695 ±	337.689 (6)	2039.353 ± 3	317.127 (6)	2633.788 ±	249.490 (6)

PA49: Summary of Cytochrome Activity Test Compound: 2,2',4,4'-Tetrabromodiphenyl Ether CAS Number: 5436-43-1 Date Report Requested: 03/11/2019 Time Report Requested: 15:21:47 Lab: Battelle

			Male: Core Males
Treatment Groups (mg/kg)			
	48	5	
Total Protein Concentration (mg/ml)	7.41 ±	1.29 (6)	
Cytochrome P450 1A1 Concentraion (ng/ml)	15.6 ±	0.8 (5)	
Cytochrome P450 1A1 Tissue Concentration (ng/mg)	2.763 ±	0.280 (6)	
Cytochrome P450 2B1 Concentration (ng/ml)	3.19 ±	0.17 (6)	
Cytochrome P450 2B1 Tissue Concentration (ng/mg)	0.472 ±	0.055 (6)	
Cytochrome P450 1A2 Concentration (ng/ml)	46.7 ±	5.6 (6)	
Cytochrome P450 1A2 Tissue Concentration (ng/mg)	7.072 ±	1.206 (6)	
JDP Glucuronosyltransferase 1 Concentration (ng/ml)	22583.917 ± 2	239.463 (6) *	
JDP Glucuronosyltransferase 1 Tissue Concentration (ng/mg)	3368.914 ±	513.011 (6)	

PA49: Summary of Cytochrome Activity Test Compound: 2,2',4,4'-Tetrabromodiphenyl Ether CAS Number: 5436-43-1 Date Report Requested: 03/11/2019 Time Report Requested: 15:21:47 Lab: Battelle

LEGEND

Data are displayed as mean ± SEM (N) unless otherwise noted.

Statistical analysis performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests (unless otherwise noted).

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

Statistical significance for the control group indicates a significant trend test

* Statistically significant at P <= 0.05

** Statistically significant at P <= 0.01

One value for Cytochrome P450 1A1 Concentration in the 0.0485 mg/kg group and one value for Cytochrome P450 1A1 Concentration in the 485 mg/kg group were excluded because they were outliers.

** END OF REPORT **